论文部分内容阅读
近日,第二批44个国家医保药品谈判结果揭开面纱:罗氏、辉瑞、拜耳、诺华以及康弘药业、微芯生物、先声药业旗下山东先声麦得津生物制药有限公司等10家成功进入医保目录的企业代表在京与人社部举行了现场签约仪式。这意味着国家医保药品谈判品种的“第二方队”组编基本定型。接下来,通过谈判成功进入国家医保目录的产品将陆续进入各省医保。外资药企降价换医保包括拜耳、罗氏、杨森、阿斯利康
Recently, the second batch of 44 countries, the results of the negotiation of Medicare drugs lifted the veil: Roche, Pfizer, Bayer, Novartis and Hong Hong Pharmaceutical, Microbiology, Ancestral Medicine subsidiary of Shandong Simaximadi Pharmaceutical Co., Ltd. and other 10 Business representatives who successfully entered the medical insurance catalog held a site signing ceremony with the Ministry of Human Resources and Social Security in Beijing. This means that the “second party team” of national drug negotiators is basically finalized. Next, the products successfully negotiated to enter the national health insurance catalog will gradually enter the provincial health insurance. Foreign pharmaceutical prices cut for Medicare include Bayer, Roche, Janssen, AstraZeneca